Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rapanone is a plant-derived alkyl-dihydroxybenzoquinone, specifically 2,5-dihydroxy-3-tridecyl-1,4-benzoquinone, primarily isolated from species such as *Ardisia crenata*. Structurally, it is a homologue of embelin, characterized by a longer tridecyl side chain. Rapanone has demonstrated significant in vitro cytotoxic activity against multiple cancer types, including prostate, thyroid, and colorectal carcinomas, often showing higher potency and better selectivity than its structural relatives or standard chemotherapeutic agents like doxorubicin. Its mechanism of action involves the induction of apoptosis, making it a candidate for further oncological research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rapanone.